Li Kang Biomedical Co Ltd - Asset Resilience Ratio
Li Kang Biomedical Co Ltd (6242) has an Asset Resilience Ratio of 13.48% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 6242 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how Li Kang Biomedical Co Ltd's Asset Resilience Ratio has changed over time. See 6242 net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Li Kang Biomedical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Li Kang Biomedical Co Ltd stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$147.30 Million | 13.48% |
| Total Liquid Assets | NT$147.30 Million | 13.48% |
Asset Resilience Insights
- Moderate Liquidity: Li Kang Biomedical Co Ltd has 13.48% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Li Kang Biomedical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Li Kang Biomedical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Trip.com Group Limited
F:CLV |
Travel Services | 11.97% |
|
Norwegian Cruise Line Holdings Ltd
NYSE:NCLH |
Travel Services | 0.00% |
|
Guangzhou Dongfang Hotel Co Ltd
SHE:000524 |
Travel Services | 0.01% |
|
Rainbow Tours SA
WAR:RBW |
Travel Services | 0.22% |
|
Issta Lines Ltd
TA:ISTA |
Travel Services | 0.27% |
|
XiAn Qujiang Cultural Tourism Co Ltd
SHG:600706 |
Travel Services | 0.94% |
|
CVC Brasil Operadora e Agencia
SA:CVCB3 |
Travel Services | 4.69% |
|
Destinasi Tirta Nusantara Tbk
JK:PDES |
Travel Services | 0.02% |
Annual Asset Resilience Ratio for Li Kang Biomedical Co Ltd (2002–2025)
The table below shows the annual Asset Resilience Ratio data for Li Kang Biomedical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 13.48% | NT$147.30 Million ≈ $4.64 Million |
NT$1.09 Billion ≈ $34.44 Million |
-24.13pp |
| 2024-12-31 | 37.61% | NT$389.45 Million ≈ $12.27 Million |
NT$1.04 Billion ≈ $32.63 Million |
+14.73pp |
| 2023-12-31 | 22.88% | NT$189.18 Million ≈ $5.96 Million |
NT$827.00 Million ≈ $26.06 Million |
+3.80pp |
| 2022-12-31 | 19.08% | NT$131.42 Million ≈ $4.14 Million |
NT$688.84 Million ≈ $21.70 Million |
+7.00pp |
| 2021-12-31 | 12.08% | NT$74.39 Million ≈ $2.34 Million |
NT$616.07 Million ≈ $19.41 Million |
-6.92pp |
| 2020-12-31 | 19.00% | NT$122.50 Million ≈ $3.86 Million |
NT$644.77 Million ≈ $20.31 Million |
+10.72pp |
| 2019-12-31 | 8.28% | NT$51.84 Million ≈ $1.63 Million |
NT$626.44 Million ≈ $19.74 Million |
+3.71pp |
| 2013-12-31 | 4.56% | NT$5.10 Million ≈ $160.68K |
NT$111.79 Million ≈ $3.52 Million |
+2.13pp |
| 2009-12-31 | 2.43% | NT$6.15 Million ≈ $193.76K |
NT$252.83 Million ≈ $7.97 Million |
-1.75pp |
| 2008-12-31 | 4.18% | NT$18.34 Million ≈ $577.78K |
NT$438.89 Million ≈ $13.83 Million |
+2.75pp |
| 2007-12-31 | 1.43% | NT$10.01 Million ≈ $315.37K |
NT$701.86 Million ≈ $22.11 Million |
-0.50pp |
| 2006-12-31 | 1.92% | NT$14.56 Million ≈ $458.66K |
NT$757.63 Million ≈ $23.87 Million |
-0.42pp |
| 2005-12-31 | 2.34% | NT$18.54 Million ≈ $584.17K |
NT$791.11 Million ≈ $24.92 Million |
-0.01pp |
| 2004-12-31 | 2.35% | NT$18.05 Million ≈ $568.55K |
NT$766.35 Million ≈ $24.14 Million |
-0.48pp |
| 2003-12-31 | 2.83% | NT$21.82 Million ≈ $687.48K |
NT$770.15 Million ≈ $24.26 Million |
+1.37pp |
| 2002-12-31 | 1.47% | NT$11.24 Million ≈ $354.00K |
NT$765.96 Million ≈ $24.13 Million |
-- |
About Li Kang Biomedical Co Ltd
Li Kang Biomedical Co., Ltd. manufactures and sells supplement, cosmeceutical, and hygienic drink products. It also engages in the management and consulting of tourism factory business; and offers telemarketing services. The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd. in September 2014. Li Kang Biomedical Co., Ltd. was founded i… Read more